The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000362:Agar; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004285:Dogs; D006801:Humans; D007930:Leucine; D007962:Leukocytes / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D010307:Parotid Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D011868:Radioisotopes; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000037:antagonists & inhibitors*; D013899:Thoracic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D013936:Thymidine; D014529:Uridine
D000970:Antineoplastic Agents; D011506:Proteins; D011868:Radioisotopes; D013438:Sulfhydryl Compounds; D012313:RNA; D000362:Agar; D004247:DNA; D007930:Leucine; D013936:Thymidine; D014529:Uridine